
PATENT

SQCKET NO.: AM100639/WYNC-0996



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Elokdah, et al. Confirmation No.: 3745

Application No.: 10/731,074 Group Art Unit: 1626

Filing Date: December 9, 2003 Examiner: Michael Barker

For: Substituted Indole Oxo-Acetyl Amino Acetic Acid Derivatives As Inhibitors of

Plasminogen Activator Inhibitor-1 (PAI-1)

DATE OF DEPOSIT: September 2, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Leslie E. Aberman

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified application as set forth in § 1.491, before the mailing date
	of a first Office Action on the merits of the above-identified application, or
	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of \$\frac{\$180.00}{}\ as set forth in \{ 1.17(p).
\boxtimes	Copies of reference numbers 14-54 listed on the attached Form PTO-1449 are
	enclosed herewith.
\boxtimes	Copies of reference numbers 1-13 listed on the attached Form PTO 1449 are
	not required to be submitted pursuant to the revisions of 37 CFR §
	1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for

DOCKET NO.: AM100639/WYNC-0996-3-

PATENT

which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

The relevance of those listed references which are not in the English language is as follows:

English language abstracts and/or equivalents have been provided for those listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 2, 2005

Leslie E. Aberman Registration No. 54,836

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

	D.a.	FO:
(F	E 4AA	Lis
SE	0 8 2005	Us S
SEE.		U.S Pa

Form PTO-1449 Modified

ist of Patent and Publications
Cited by Applicant
Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket No.
AM100639/WYNC-0996

Application No. 10/731,074

Applicant Elokdah, et al.

Filing Date
December 9, 2003

Group 1626

Confirmation No. 3745

U. S. PATENT DOCUMENTS

Examiner		Document				
Initial		No.	Date	Name	Class	Subclass
	1	3,843,683	10/22/74	Bell	548	493
	2	4,736,043	04/05/88	Michel et al.	548	492
	3	5,612,360	03/18/97	Boyd et al.	514	381
	4	6,048,875	04/11/00	De Nanteuil et al.	514	314
	5	6,110,963	08/29/00	Malamas	514	443
	6	6,251,936	06/26/01	Wrobel et al.	514	443
	7	6,302,837 B1	10/16/01	De Nanteuil et al.	514	337
	8	6,787,556	09/07/04	Hargreaves et al.	514	311
	9	6,800,645	10/05/04	Cox et al.	514	314
	10	6,800,654	10/05/04	Mayer et al.	514	381
	11	6,844,358	01/18/05	Malamas et al.	514	336
	12	2003/0060497 A1	03/27/03	Gerlach	514	414
	13	2004/0204417 A1	10/14/04	Perez et al.	514	249
	ļ					

FY	AT	MIN	JED

Form PTO-1449 Modified	Docket No. AM100639/WYNC-0996	Application No. 10/731,074
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Elokdah, et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date December 9, 2003	Group 1626
	Confirmation No. 3745	

FOREIGN PATENT DOCUMENTS

Examiner					Translation	
Initial		Document No.	Date	Country	YES	NO
	14	19543639 A1	05/28/97	Germany	X abstract	
	15	43 38 770 A1	05/18/95	Germany (WO 95/13266)	X abstract	
	16	19753522	06/10/99	Germany	X abstract	
	17	1 321 433	06/27/73	GB		
	18	0 416 609 A2	03/13/91	EP		
	19	0 508 723 A1	10/14/92	EP		
	20	0 512 570 A1	11/11/92	EP		
	21	0 540 956 A1	05/12/93	EP		-
	22	0 819 686 A1	01/21/98	EP		
	23	0 955 299 A1	11/10/99	EP (US 6048875)	X abstract	
•	24	1 156 045 A1	11/21/01	EP		
	25	00/046197 A1	08/10/00	wo		
	26	00/32180 A2	06/08/00	wo		
	27	00/35919 A1	06/22/00	wo		
	28	00/46195 A1	08/10/00	wo		
	29	01/12187 A2	02/22/01	wo		
	30	02/030895 A1	04/18/02	wo		
	31	02/072549 A1	09/19/02	wo		
	32	03/000253 A1	01/03/03	wo		

EXAMINER	DATE CONSIDERED
	<u></u>

Form PTO-1449 Modified	Docket No. AM100639/WYNC-0996	Application No. 10/731,074				
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Elokdah, et al.					
U.S. Department of Commerce Patent and Trademark Office	Filing Date December 9, 2003	Group 1626				
	Confirmation No. 3745					
EODELCH DA MENTE DO CHIA EDITEC						

FOREIGN PATENT DOCUMENTS

Examiner	Document No.	Date Country	Translation			
Initial			YES	NO		
	33	03/031409 A1	04/17/03	wo		
	34	03/087087 A2	10/23/03	wo		
	35	2004/052854 A2	06/24/04	wo		
	36	94/14434 A1	07/07/94	wo		
	37	94/26738 A1	11/24/94	wo		
	38	95/10513 A1	04/20/95	wo		
	39	96/06840 A1	03/07/96	wo		
	40	96/21656 A1	07/18/96	wo		
	41	97/09308 A1	03/13/97	wo		
	42	97/43260 A1	11/20/97	wo		
	43	97/48697 A1	12/24/97	wo		
	44	98/08818 A1	03/05/98	wo		
	45	99/43672 A1	09/02/99	wo		
	46	99/46260 A1	09/16/99	wo		
	47	99/50268 A1	10/07/99	wo		
	48	99/58519 A1	11/18/99	wo		
	49	99/61435 A1	12/02/99	wo		
						=

EXAMINER	DATE CONSIDERED

Form PTO-1449 Modified			Docket No. AM100639/WYNC-0996	Application No. 10/731,074	
7 11			Applicant Elokdah, et al.		
		nent of Commerce Frademark Office	Filing Date December 9, 2003	Group 1626	
			Confirmation No. 3745		
O	ГНЕ	R DOCUMENTS (Includ	ing Author, Title, Date, Per	tinent Pages, Etc.)	
	50		chibiting oral in-vivo efficacy	ive evaluation of a structurally y," Journal of Thrombosis and	
	51	Guzzo, P.R. et al., "Synthesis of a conformationally constrained threonin-valine dipeptide mimetic: design of a potential inhibitor of plasminogen activator inhibitor-1," <i>Tetrahedron Letters</i> , 43(1), 41-43 (2002)			
	52	Charlton, Peter, "The status of plasminogen activator inhibitor-1 as a therapeutic target," Expert <i>Opinion On Investigational Drugs</i> , (May 1997), vol. 6, no. 5, pages 539-554			
	53	Malamas, M.S. et al., "Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy," <i>Journal of Medicinal Chemistry</i> , 43(7):1293-1310			
	54		eaction of indole derivatives on," <i>J Org Chem</i> , 1970, 35(8)		

EXAMINER	DATE CONSIDERED
----------	-----------------